SLDB
vs
S&P 500
SLDB
S&P 500
Over the past 12 months, SLDB has outperformed S&P 500, delivering a return of +27% compared to the S&P 500's +15% growth.
Stocks Performance
SLDB vs S&P 500
Performance Gap
SLDB vs S&P 500
Performance By Year
SLDB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Solid Biosciences Inc
Glance View
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2018-01-26. Duchenne is a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are its gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. SGT-001 is its lead gene transfer candidate and utilizes an adeno-associated virus (AAV)9 vector. In addition to its gene transfer candidates, it has development programs focusing on platform technologies, including dual gene expression, a technology that allows it to package multiple transgenes into one vector, as well as capsids. The company is developing SGT-001 for the treatment of Duchenne through a single intravenous administration.